Ozempic (semaglutide) clinical trials

Semaglutide as an add-on treatment to optimise glycaemic control in children and young people with type 1 diabetes (Smile T1D)

This study, called SMILE T1D, is looking at whether a medicine called semaglutide (also known as Ozempic) can help young people aged 10-24 with Type 1 diabetes better manage their blood sugar. Participants would continue their usual diabetes care, with some also receiving the study medicine.